RxDoctor Payments Data

Lourdes Pena de la Vega, MD

Nephrology · Manati, PRNPI 1134273394

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $2,040 of the $2,981 with a category attached, or 68.4%. Johnson & Johnson accounts for 79.1% of it on its own, with 7 other manufacturers making up the rest. Reporting peaked in 2019 at $2,403 and has fallen 96.1% since, to $95 in 2025.

$2,981in general payments, 2019–2025

Across 13 payments — averaging $229.31 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$2K
  • AstraZeneca$248
  • BD$95
  • Bard Peripheral Vascular, Inc.$82
  • Mallinckrodt Hospital Products Inc.$75
  • Bayer$65
  • plus $60 from 2 others

What the payments were for

  • Consulting fees$2,04068%
  • Travel & lodging$2107%
  • Food & beverage$65622%
  • Education$753%

General payments by program year

19
20
21
22
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,981 in reported general payments places this provider in the 70th percentile of 161 nephrology providers in Puerto Rico.

See all nephrology providers in Puerto Rico

Medicare billing

Part B allowed, 2024
$25,588
Medicare patients
52
Services billed
180

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
FarxigaDapagliflozin Propanediol455$285,076
LokelmaSodium Zirconium Cyclosilicate108$63,920
TradjentaLinagliptin101$60,970
JardianceEmpagliflozin84$54,973
Lanthanum Carbonate110$46,440
Sevelamer Carbonate250$37,374
OzempicSemaglutide34$33,065
EliquisApixaban54$32,577
Calcium Acetate321$30,368
KerendiaFinerenone47$25,183
JanuviaSitagliptin Phosphate31$19,877
SynthroidLevothyroxine Sodium166$9,809
Calcitriol1,480$9,479
RetacritEpoetin Alfa-Epbx23$8,086
Lagevrio (Eua)Molnupiravir12$7,681

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga, Lokelma$248$348,996563 claims
BayerKerendia$65$25,18347 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 161 nephrology providers in Puerto Rico.

Other nephrology in Manati

See the full list for Puerto Rico

Where these figures come from

Is this you, or does something look wrong? →